HKSE - Delayed Quote ? HKD Zai Lab Limited (9688.HK) Follow Compare 22.850 +1.300 (+6.03%) As of 2:05 PM GMT+8. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Zai Lab Announces Participation in November and December Investor Conferences SHANGHAI & CAMBRIDGE, Mass., October 18, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November and December 2024: Business Wire ? 4 days ago ZLAB Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 SHANGHAI & CAMBRIDGE, Mass., October 17, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will hold an investor webcast to discuss data from a Phase 1 clinical trial of ZL-1310, the Company’s investigational DLL3-targeted antibody-drug conjugate (ADC), in patients with advanced stage small cell lung cancer (SCLC). The live conference call and webcast will take place on Thursday, October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT). Business Wire ? 5 days ago ZLAB Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024 SHANGHAI & CAMBRIDGE, Mass., October 16, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the third quarter of 2024 and recent corporate updates, before the opening of the U.S. equity markets on Tuesday, November 12, 2024. The Company will host a live conference call and webcast on the same date, at 8:00 a.m. ET (9:00 p.m. HKT). Business Wire ? 6 days ago ZLAB Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024 SHANGHAI & CAMBRIDGE, Mass., October 09, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; "Zai Lab") today announced that data from a Phase 1 study of ZL-1310, the Company’s investigational antibody-drug conjugate (ADC), will be presented during a plenary session at the EORTC-NCI-AACR Symposium (ENA) 2024 taking place October 23-25, in Barcelona, Spain. The preliminary results from the ongoing, open-label, multicenter clinical trial (NCT06179069) will address the potential of ZL-1310 as a novel Business Wire ? 13 days ago ZLAB High Growth Tech Stocks To Watch In September 2024 Over the last 7 days, the market has remained flat, but it is up 32% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks that can capitalize on these trends is crucial for investors seeking robust returns. Simply Wall St. ? 25 days ago SBGI WBTN ZLAB Zai Lab Limited (ZLAB) Surges 11.1%: Is This an Indication of Further Gains? Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. Zacks ? 25 days ago ZLAB TELA Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024 SHANGHAI & CAMBRIDGE, Mass., September 17, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; "Zai Lab") today announced that data from a preclinical study of ZL-1503, the company’s internally discovered IL-13/IL-31 bispecific antibody for the treatment of atopic dermatitis (AD), will be presented in a late-breaking oral presentation at the European Academy of Dermatology and Venerology Congress (EADV) 2024 taking place September 25-28 in Amsterdam, Netherlands. The results will address the potent Business Wire ? last month ZLAB Zai Lab Limited (ZLAB): Top ADR Stock According to Hedge Funds We recently compiled a list of the Top 10 ADR Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against the other ADR stocks. Diversifying an investment portfolio is one of the best ways of spreading risk and minimizing the impact […] Insider Monkey ? last month ZLAB Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024 SHANGHAI & CAMBRIDGE, Mass., August 27, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from a Phase 1 study of ZL-1218, the company’s anti-CCR8 antibody, will be presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13-17, 2024, in Barcelona, Spain. The preliminary results from the ongoing dose-escalation clinical trial (NCT05859464) will highlight the potential of ZL-1218 to reduce regulatory T cells an Business Wire ? last month ZLAB High Growth Tech Stocks To Watch: Vertex And 2 Other Top Picks As global markets rally on the back of anticipated interest rate cuts, small-cap stocks have been outperforming their larger counterparts, signaling a renewed investor confidence in growth sectors. In this favorable climate, identifying high-growth tech stocks with robust fundamentals and innovative edge becomes crucial for investors seeking to capitalize on market momentum. Simply Wall St. ? last month ZLAB VERX Zai Lab Announces Participation in September Investor Conferences SHANGHAI & CAMBRIDGE, Mass., August 22, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in September 2024: Business Wire ? last month ZLAB Zai Lab Limited (NASDAQ:ZLAB) institutional owners may be pleased with recent gains after 25% loss over the past year Key Insights Given the large stake in the stock by institutions, Zai Lab's stock price might be vulnerable to their... Simply Wall St. ? 2 months ago ZLAB Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates SHANGHAI & CAMBRIDGE, Mass., August 06, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2024, along with recent product highlights and corporate updates. Business Wire ? 2 months ago ZLAB Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem It’s not often that a genuine hidden-gem candidate appears in the market. But that label might apply to Chinese biotechnology firm Zai Lab (NASDAQ:ZLAB). Developing and commercializing a range of therapeutics, the company offers solutions for autoimmune disorders, infectious diseases and neurologic conditions. Arguably the most compelling business unit undergirding ZLAB stock, though, is oncology. According to its public profile, Zai Lab features a cancer therapy called Optune. This innovation u InvestorPlace ? 2 months ago ZLAB China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG The BLA for efgartigimod alfa injection was supported by positive data from the international Phase III ADAPT-SC clinical trial. Pharmaceutical Technology ? 3 months ago ZLAB Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China SHANGHAI & CAMBRIDGE, Mass., July 16, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration (NMPA) approved the Biologics License Application (BLA) for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC), 1,000mg (5.6ml)/vial indicated as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine recept Business Wire ? 3 months ago ZLAB ARGNF ARGX Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy SHANGHAI & CAMBRIDGE, Mass., July 15, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data published in the journal Cell demonstrate that neoadjuvant monotherapy with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib results in a high response rate and reshapes the tumor microenvironment (TME), providing new targets for immunotherapy and combination regimens in patients with homologous recombination deficiency (HRD) positive ovarian cancer. The study revealed nira Business Wire ? 3 months ago ZLAB Best Momentum Stocks to Buy for July 10th KGC, ZLAB, and EAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 10, 2024. Zacks ? 3 months ago KGC ZLAB EAT Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024 SHANGHAI, China & CAMBRIDGE, Mass., July 10, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the second quarter of 2024 and recent corporate updates, after the closing of the U.S. equity markets on Tuesday, August 6, 2024. The Company will host a live conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. ET (8:00 p.m. HKT). Business Wire ? 3 months ago ZLAB Insider Selling: Chairperson & CEO Ying Du Sells Shares of Zai Lab Ltd (ZLAB) On June 26, 2024, Ying Du, Chairperson & CEO of Zai Lab Ltd (NASDAQ:ZLAB), executed a sale of 23,939 shares of the company, according to the SEC Filing. Zai Lab Ltd (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for cancer, autoimmune, and infectious diseases. Over the past year, Ying Du has sold a total of 38,106 shares of Zai Lab Ltd and has not made any purchases of the stock. GuruFocus.com ? 3 months ago ZLAB Performance Overview Trailing total returns as of 10/23/2024, which may include dividends or other distributions. Benchmark is HANG SENG INDEX Return 9688.HK HANG SENG INDEX YTD +6.28% +21.74% 1-Year +23.78% +20.86% 3-Year -70.89% -20.57%
